America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does AOH1996 selectively target cancer cells without affecting healthy cells?
**Interview with Dr. Linda Malkas on New Breakthrough in Cancer Treatment**
**Editor:** Thank you for joining us today, Dr. Malkas. Can you start by explaining the significance of the AOH1996 molecule in cancer treatment?
**Dr. Malkas:** Absolutely. AOH1996 is a groundbreaking molecule that targets a variant of the PCNA protein, which plays a crucial role in DNA replication and tumor growth. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, our approach selectively destroys cancer cells, minimizing side effects and improving patient outcomes.
**Editor:** That sounds promising! What do you mean by saying it acts like a ‘blizzard that can shut down an airline’s main hub’?
**Dr. Malkas:** The analogy illustrates how AOH1996 disrupts the normal cycle of cancer cell reproduction. Just as a blizzard can halt all flights, our drug targets the cancer cells at their core, effectively stopping their proliferation while leaving healthy cells untouched.
**Editor:** You’ve mentioned that this research has shown effectiveness across multiple types of cancer. Can you specify which cancers have responded well to this treatment?
**Dr. Malkas:** Yes, in our clinical research, AOH1996 has proven effective in treating breast, prostate, brain, ovarian, cervical, skin, and lung cancers. The breadth of its applicability is one of the reasons we’re so excited about its potential.
**Editor:** What are the next steps in this research?
**Dr. Malkas:** The next phase involves moving our findings into human clinical trials. We’ve shown promising results in vitro, and we’re hopeful that these results will translate into successful treatments for patients in the near future.
**Editor:** It’s encouraging to hear about these advancements. How long do you anticipate it will take before AOH1996 could become available to patients?
**Dr. Malkas:** While it’s hard to give a precise timeline, we are optimistic that we can progress through the necessary trials and regulatory processes within a few years. Our team is dedicated to accelerating this development for the benefit of patients.
**Editor:** Thank you, Dr. Malkas, for sharing these insights with us. It’s an exciting time in cancer research, and we look forward to hearing more about AOH1996.
**Dr. Malkas:** Thank you for having me. I’m looking forward to sharing more breakthroughs as we continue our work.
